VCYT
Veracyte, Inc.43.22
-0.31-0.71%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.42BP/E (TTM)
113.74Basic EPS (TTM)
0.38Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Veracyte posted solid Q2 revenue growth of 14% year-over-year to $130.2M, driven by 18% higher testing volume from Decipher Prostate and Afirma, though a $20.5M non-cash impairment on its French subsidiary assets flipped operations to a $5.3M loss from last year's $4.6M profit. Gross margins held steady at 69%, while YTD net income climbed 57% to $6.1M with diluted EPS of $0.08 on 79.9M shares, reconciling cleanly to reported figures. Operating cash flow surged to $39.0M, yielding $35.9M free cash flow after $3.1M capex (derived), bolstering liquidity to $320.7M in cash and equivalents with no debt. The C2i acquisition from February 2024 added $25.3M in developed technology intangibles amortized over 14 years, enhancing MRD capabilities. Yet regulatory hurdles in reimbursement persist as a key risk.
8-K
Veracyte Q2 revenue up 14%
Veracyte reported Q2 2025 revenue of $130.2 million, up 14% year-over-year, with testing revenue hitting $122.3 million on 18% volume growth to 42,441 tests; Decipher surged 24% to $76.3 million, while Afirma rose 5% to $43.4 million. The company completed the sale of its French subsidiary's manufacturing operations to Helio Diagnostics on August 1, 2025, taking a $20.5 million impairment charge but deconsolidating the entity. Strong results prompted raised full-year testing revenue guidance to $477–$483 million and adjusted EBITDA margin to 23.5%. Resolution frees capital for strategic investments.
8-K
Veracyte approves equity plan boost
Veracyte's stockholders approved all key proposals at the June 17, 2025 Annual Meeting, electing seven directors including Eliav Barr and Jens Holstein to serve until 2026. They ratified Ernst & Young as auditors for 2025, endorsed executive compensation on an advisory basis, and selected annual say-on-pay votes going forward. Crucially, they greenlit an amendment adding 2,500,000 shares to the 2023 Equity Incentive Plan, bolstering talent retention amid growth. This signals strong governance alignment, yet dilutes shares slightly.
10-Q
Q1 FY2025 results
Veracyte swung to a $7.0 million net profit in Q1 FY2025 ended March 31, 2025, up from a $1.9 million loss a year earlier, as revenue climbed 18% year-over-year to $114.5 million on 23% higher testing volume despite a 3% average selling price dip (derived). Gross margins expanded to 69.5% from 64.5%, fueled by testing revenue growth in Decipher Prostate and Afirma, while Envisia dipped; operating income hit $2.9 million versus a $4.7 million loss. Cash from operations reached $5.4 million, with $287.4 million in cash and equivalents at quarter-end, no debt, and $16.0 million potential C2i milestone payouts looming. The February 2024 C2i buyout for $100.2 million (mostly stock, $17.2 million contingent) added $8.5 million to goodwill via currency effects and bolstered MRD tech with $23.3 million in developed assets (14-year life). Litigation shadows progress, though—patent suits against rivals like Sonic Healthcare could drag on reimbursements.
8-K
Q1 revenue up 18%, strong growth
Veracyte kicked off 2025 with Q1 revenue surging 18% to $114.5 million, fueled by 22% testing volume growth to 40,655 tests, while Decipher jumped 33% to $66.6 million. Net income flipped to $7.0 million from a prior loss, with adjusted EBITDA hitting $24.7 million or 21.6% of revenue. Yet Marseille operations face bankruptcy proceedings after funding cuts, expected to wrap by year-end. The company raised full-year adjusted EBITDA guidance to 22.5% of revenue.
IPO
Website
Employees
Sector
Industry
ACUT
Accustem Sciences Inc.
0.70-0.05
AVCRF
Avricore Health Inc.
0.05+0.02
BDSX
Biodesix, Inc.
7.90+0.38
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CSTL
Castle Biosciences, Inc.
39.05+0.17
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
IMDX
Insight Molecular Diagnostics I
5.10+0.08
VRAX
Virax Biolabs Group Limited
0.40-0.01